Diseases, Conditions, Syndromes

Lower risk of gastrointestinal bleeding for apixaban

(HealthDay)—For patients receiving direct oral anticoagulant (DOAC) agents for non-valvular atrial fibrillation, apixaban is associated with a lower risk of gastrointestinal (GI) bleeding than rivaroxaban or dabigatran, ...

Cardiology

No increase in bleeding complications with rivaroxaban post-ACS

Patients with acute coronary syndrome who were treated with the blood-thinning drug rivaroxaban in addition to an antiplatelet medication (clopidogrel or ticagrelor) experienced no increase in bleeding complications compared ...

Cardiology

Non-vitamin K oral anticoagulants vary in assay effects

(HealthDay)—Non-vitamin K oral anticoagulants exhibit variable effects on coagulation assays, according to a study published in the Sept. 16 issue of the Journal of the American College of Cardiology.

Diseases, Conditions, Syndromes

Rivaroxaban found noninferior to enoxaparin in acutely ill

(HealthDay)—In acutely ill hospitalized patients, standard-duration rivaroxaban has similar efficacy as enoxaparin in reducing the risk of venous thromboembolism, while extended-duration rivaroxaban has superior efficacy, ...

Medications

Xarelto's approval expanded

(HealthDay)—Approval of the anti-clotting drug Xarelto (rivaroxaban) has been expanded by the U.S. Food and Drug Administration to include treating deep vein thrombosis (DVT) or pulmonary embolism.

Cardiology

Stroke risk high when anti-clotting drugs stopped

Some patients with irregular heartbeats who are taken off anti-clotting medication face a high risk of stroke or blood clotting within a month, according to new research presented at the American Heart Association's Emerging ...

page 3 from 4